Cargando…

How ‘place’ matters for addressing the HIV epidemic: evidence from the HPTN 071 (PopART) cluster-randomised controlled trial in Zambia and South Africa

BACKGROUND: In a cluster-randomised trial (CRT) of combination HIV prevention (HPTN 071 (PopART)) in 12 Zambian communities and nine South African communities, carried out from 2012 to 2018, the intervention arm A that offered HIV treatment irrespective of CD4 count did not have a significant impact...

Descripción completa

Detalles Bibliográficos
Autores principales: Bond, Virginia, Hoddinott, Graeme, Viljoen, Lario, Ngwenya, Fredrick, Simuyaba, Melvin, Chiti, Bwalya, Ndubani, Rhoda, Makola, Nozizwe, Donnell, Deborah, Schaap, Ab, Floyd, Sian, Hargreaves, James, Shanaube, Kwame, Fidler, Sarah, Bock, Peter, Ayles, Helen, Hayes, Richard, Simwinga, Musonda, Seeley, Janet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025534/
https://www.ncbi.nlm.nih.gov/pubmed/33823907
http://dx.doi.org/10.1186/s13063-021-05198-5
_version_ 1783675514978828288
author Bond, Virginia
Hoddinott, Graeme
Viljoen, Lario
Ngwenya, Fredrick
Simuyaba, Melvin
Chiti, Bwalya
Ndubani, Rhoda
Makola, Nozizwe
Donnell, Deborah
Schaap, Ab
Floyd, Sian
Hargreaves, James
Shanaube, Kwame
Fidler, Sarah
Bock, Peter
Ayles, Helen
Hayes, Richard
Simwinga, Musonda
Seeley, Janet
author_facet Bond, Virginia
Hoddinott, Graeme
Viljoen, Lario
Ngwenya, Fredrick
Simuyaba, Melvin
Chiti, Bwalya
Ndubani, Rhoda
Makola, Nozizwe
Donnell, Deborah
Schaap, Ab
Floyd, Sian
Hargreaves, James
Shanaube, Kwame
Fidler, Sarah
Bock, Peter
Ayles, Helen
Hayes, Richard
Simwinga, Musonda
Seeley, Janet
author_sort Bond, Virginia
collection PubMed
description BACKGROUND: In a cluster-randomised trial (CRT) of combination HIV prevention (HPTN 071 (PopART)) in 12 Zambian communities and nine South African communities, carried out from 2012 to 2018, the intervention arm A that offered HIV treatment irrespective of CD4 count did not have a significant impact on population level HIV incidence. Intervention arm B, where HIV incidence was reduced by 30%, followed national guidelines that mid trial (2016) changed from starting HIV treatment according to a CD4 threshold of 500 to universal treatment. Using social science data on the 21 communities, we consider how place (community context) might have influenced the primary outcome result. METHODS: A social science component documented longitudinally the context of trial communities. Data were collected through rapid qualitative assessment, interviews, group discussions and observations. There were a total of 1547 participants and 1127 observations. Using these data, literature and a series of qualitative analysis steps, we identified key community characteristics of relevance to HIV and triangulated these with HIV community level incidence. RESULTS: Two interdependent social factors were relevant to communities’ capability to manage HIV: stability/instability and responsiveness/resistance. Key components of stability were social cohesion; limited social change; a vibrant local economy; better health, education and recreational services; strong institutional presence; established middle-class residents; predictable mobility; and less poverty and crime. Key components of responsiveness were community leadership being open to change, stronger history of HIV initiatives, willingness to take up HIV services, less HIV-related stigma and a supported and enterprising youth population. There was a clear pattern of social factors across arms. Intervention arm A communities were notably more resistant and unstable. Intervention arm B communities were overall more responsive and stable. CONCLUSIONS: In the specific case of the dissonant primary outcome results from the HPTN 071 (PopART) trial, the chance allocation of less stable, less responsive communities to arm A compared to arm B may explain some of the apparently smaller impact of the intervention in arm A. Stability and responsiveness appear to be two key social factors that may be relevant to secular trends in HIV incidence. We advocate for a systematic approach, using these factors as a framework, to community context in CRTs and monitoring HIV prevention efforts. TRIAL REGISTRATION: ClinicalTrials.gov NCT01900977. Registered on July 17, 2013.    SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-021-05198-5.
format Online
Article
Text
id pubmed-8025534
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80255342021-04-08 How ‘place’ matters for addressing the HIV epidemic: evidence from the HPTN 071 (PopART) cluster-randomised controlled trial in Zambia and South Africa Bond, Virginia Hoddinott, Graeme Viljoen, Lario Ngwenya, Fredrick Simuyaba, Melvin Chiti, Bwalya Ndubani, Rhoda Makola, Nozizwe Donnell, Deborah Schaap, Ab Floyd, Sian Hargreaves, James Shanaube, Kwame Fidler, Sarah Bock, Peter Ayles, Helen Hayes, Richard Simwinga, Musonda Seeley, Janet Trials Research BACKGROUND: In a cluster-randomised trial (CRT) of combination HIV prevention (HPTN 071 (PopART)) in 12 Zambian communities and nine South African communities, carried out from 2012 to 2018, the intervention arm A that offered HIV treatment irrespective of CD4 count did not have a significant impact on population level HIV incidence. Intervention arm B, where HIV incidence was reduced by 30%, followed national guidelines that mid trial (2016) changed from starting HIV treatment according to a CD4 threshold of 500 to universal treatment. Using social science data on the 21 communities, we consider how place (community context) might have influenced the primary outcome result. METHODS: A social science component documented longitudinally the context of trial communities. Data were collected through rapid qualitative assessment, interviews, group discussions and observations. There were a total of 1547 participants and 1127 observations. Using these data, literature and a series of qualitative analysis steps, we identified key community characteristics of relevance to HIV and triangulated these with HIV community level incidence. RESULTS: Two interdependent social factors were relevant to communities’ capability to manage HIV: stability/instability and responsiveness/resistance. Key components of stability were social cohesion; limited social change; a vibrant local economy; better health, education and recreational services; strong institutional presence; established middle-class residents; predictable mobility; and less poverty and crime. Key components of responsiveness were community leadership being open to change, stronger history of HIV initiatives, willingness to take up HIV services, less HIV-related stigma and a supported and enterprising youth population. There was a clear pattern of social factors across arms. Intervention arm A communities were notably more resistant and unstable. Intervention arm B communities were overall more responsive and stable. CONCLUSIONS: In the specific case of the dissonant primary outcome results from the HPTN 071 (PopART) trial, the chance allocation of less stable, less responsive communities to arm A compared to arm B may explain some of the apparently smaller impact of the intervention in arm A. Stability and responsiveness appear to be two key social factors that may be relevant to secular trends in HIV incidence. We advocate for a systematic approach, using these factors as a framework, to community context in CRTs and monitoring HIV prevention efforts. TRIAL REGISTRATION: ClinicalTrials.gov NCT01900977. Registered on July 17, 2013.    SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-021-05198-5. BioMed Central 2021-04-06 /pmc/articles/PMC8025534/ /pubmed/33823907 http://dx.doi.org/10.1186/s13063-021-05198-5 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Bond, Virginia
Hoddinott, Graeme
Viljoen, Lario
Ngwenya, Fredrick
Simuyaba, Melvin
Chiti, Bwalya
Ndubani, Rhoda
Makola, Nozizwe
Donnell, Deborah
Schaap, Ab
Floyd, Sian
Hargreaves, James
Shanaube, Kwame
Fidler, Sarah
Bock, Peter
Ayles, Helen
Hayes, Richard
Simwinga, Musonda
Seeley, Janet
How ‘place’ matters for addressing the HIV epidemic: evidence from the HPTN 071 (PopART) cluster-randomised controlled trial in Zambia and South Africa
title How ‘place’ matters for addressing the HIV epidemic: evidence from the HPTN 071 (PopART) cluster-randomised controlled trial in Zambia and South Africa
title_full How ‘place’ matters for addressing the HIV epidemic: evidence from the HPTN 071 (PopART) cluster-randomised controlled trial in Zambia and South Africa
title_fullStr How ‘place’ matters for addressing the HIV epidemic: evidence from the HPTN 071 (PopART) cluster-randomised controlled trial in Zambia and South Africa
title_full_unstemmed How ‘place’ matters for addressing the HIV epidemic: evidence from the HPTN 071 (PopART) cluster-randomised controlled trial in Zambia and South Africa
title_short How ‘place’ matters for addressing the HIV epidemic: evidence from the HPTN 071 (PopART) cluster-randomised controlled trial in Zambia and South Africa
title_sort how ‘place’ matters for addressing the hiv epidemic: evidence from the hptn 071 (popart) cluster-randomised controlled trial in zambia and south africa
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025534/
https://www.ncbi.nlm.nih.gov/pubmed/33823907
http://dx.doi.org/10.1186/s13063-021-05198-5
work_keys_str_mv AT bondvirginia howplacemattersforaddressingthehivepidemicevidencefromthehptn071popartclusterrandomisedcontrolledtrialinzambiaandsouthafrica
AT hoddinottgraeme howplacemattersforaddressingthehivepidemicevidencefromthehptn071popartclusterrandomisedcontrolledtrialinzambiaandsouthafrica
AT viljoenlario howplacemattersforaddressingthehivepidemicevidencefromthehptn071popartclusterrandomisedcontrolledtrialinzambiaandsouthafrica
AT ngwenyafredrick howplacemattersforaddressingthehivepidemicevidencefromthehptn071popartclusterrandomisedcontrolledtrialinzambiaandsouthafrica
AT simuyabamelvin howplacemattersforaddressingthehivepidemicevidencefromthehptn071popartclusterrandomisedcontrolledtrialinzambiaandsouthafrica
AT chitibwalya howplacemattersforaddressingthehivepidemicevidencefromthehptn071popartclusterrandomisedcontrolledtrialinzambiaandsouthafrica
AT ndubanirhoda howplacemattersforaddressingthehivepidemicevidencefromthehptn071popartclusterrandomisedcontrolledtrialinzambiaandsouthafrica
AT makolanozizwe howplacemattersforaddressingthehivepidemicevidencefromthehptn071popartclusterrandomisedcontrolledtrialinzambiaandsouthafrica
AT donnelldeborah howplacemattersforaddressingthehivepidemicevidencefromthehptn071popartclusterrandomisedcontrolledtrialinzambiaandsouthafrica
AT schaapab howplacemattersforaddressingthehivepidemicevidencefromthehptn071popartclusterrandomisedcontrolledtrialinzambiaandsouthafrica
AT floydsian howplacemattersforaddressingthehivepidemicevidencefromthehptn071popartclusterrandomisedcontrolledtrialinzambiaandsouthafrica
AT hargreavesjames howplacemattersforaddressingthehivepidemicevidencefromthehptn071popartclusterrandomisedcontrolledtrialinzambiaandsouthafrica
AT shanaubekwame howplacemattersforaddressingthehivepidemicevidencefromthehptn071popartclusterrandomisedcontrolledtrialinzambiaandsouthafrica
AT fidlersarah howplacemattersforaddressingthehivepidemicevidencefromthehptn071popartclusterrandomisedcontrolledtrialinzambiaandsouthafrica
AT bockpeter howplacemattersforaddressingthehivepidemicevidencefromthehptn071popartclusterrandomisedcontrolledtrialinzambiaandsouthafrica
AT ayleshelen howplacemattersforaddressingthehivepidemicevidencefromthehptn071popartclusterrandomisedcontrolledtrialinzambiaandsouthafrica
AT hayesrichard howplacemattersforaddressingthehivepidemicevidencefromthehptn071popartclusterrandomisedcontrolledtrialinzambiaandsouthafrica
AT simwingamusonda howplacemattersforaddressingthehivepidemicevidencefromthehptn071popartclusterrandomisedcontrolledtrialinzambiaandsouthafrica
AT seeleyjanet howplacemattersforaddressingthehivepidemicevidencefromthehptn071popartclusterrandomisedcontrolledtrialinzambiaandsouthafrica
AT howplacemattersforaddressingthehivepidemicevidencefromthehptn071popartclusterrandomisedcontrolledtrialinzambiaandsouthafrica